Joseph Okafor

Dr. Joseph Okafor

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
JOJoseph Okafor
Joseph Okafor
RKRajdeep Khattar
Rajdeep Khattar
VKVasileios Kouranos
Vasileios Kouranos
SOShreya Ohri
Shreya Ohri
DDDavide Diana
Davide Diana
KWKshama Wechalekar
Kshama Wechalekar

1 February 2024 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
MNMuhummad Sohaib Nazir
Muhummad Sohaib Nazir
JOJoseph Okafor
Joseph Okafor
TMTheodore Murphy
Theodore Murphy
MAMaria Sol Andres
Maria Sol Andres
SRSivatharshini Ramalingham
Sivatharshini Ramalingham
ALAlexander R. Lyon
Alexander R. Lyon
Purpose To compare left ventricular ejection fraction (LVEF) measured with echocardiography and cardiac MRI in individuals with cancer and suspected cardiotoxicity and assess the potential effect on downstream clinical decision-making. Materials and Methods In this prospective, single-center observational cohort study, participants underwent same-day two-dimensional (2D) echocardiography and cardiac MRI between 2011 and 2021. Participants with suboptimal image quality were excluded. A subset of 74 participants also underwent three-dimensional (3D) echocardiography. The agreement of LVEF derived from each modality was assessed using Bland-Altman analysis and at relevant thresholds for cardiotoxicity. Results A total of 745 participants (mean age, 60 years ± 5 [SD]; 460 [61.7%] female participants) underwent same-day echocardiography and cardiac MRI. According to Bland-Altman analysis, the mean bias was -3.7% ± 7.6 (95% limits of agreement [LOA]: -18.5% to 11.1%) for 2D echocardiography versus cardiac MRI. In 74 participants who underwent cardiac MRI, 3D echocardiography, and 2D echocardiography, the mean LVEFs were 60.0% ± 10.4, 58.4% ± 9.4, and 57.2% ± 8.9, respectively (P < .001). At the 50% LVEF threshold for detection of cardiotoxicity, there was disagreement for 9.3% of participants with 2D echocardiography and cardiac MRI. Agreement was better with 3D echocardiography and cardiac MRI (mean bias, -1.6% ± 6.3 [95% LOA: -13.9% to 10.7%]) compared with 2D echocardiography and cardiac MRI (mean bias, -2.8% ± 6.3 [95% LOA: -15.2% to 9.6%]; P = .016). Conclusion Two-dimensional echocardiography had variations of ±15% for LVEF measurement compared with cardiac MRI in participants with cancer and led to misclassification of approximately 10% of participants for cardiotoxicity detection. Three-dimensional echocardiography had better agreement with cardiac MRI and should be used as first-line imaging. Keywords: Echocardiography, MR Functional Imaging, Cardiac Supplemental material is available for this article. © RSNA, 2024.

29 July 2023 in Life
Verified
Journal Article
Open access
PDF file
JOJoseph Okafor
Joseph Okafor
RKRajdeep Khattar
Rajdeep Khattar
RSRakesh Sharma
Rakesh Sharma
VKVasileios Kouranos
Vasileios Kouranos
Cardiac sarcoidosis (CS) is a rare inflammatory disorder characterised by the presence of non-caseating granulomas within the myocardium. Contemporary studies have revealed that 25–30% of patients with systemic sarcoidosis have cardiac involvement, with detection rates increasing in the era of advanced cardiac imaging. The use of late gadolinium enhancement cardiac magnetic resonance and 18fluorodeoxy glucose positron emission tomography (FDG-PET) imaging has superseded endomyocardial biopsy for the diagnosis of CS. Echocardiography has historically been used as a screening tool with abnormalities triggering the need for advanced imaging, and as a tool to assess cardiac function. Regional wall thinning or aneurysm formation in a noncoronary distribution may indicate granuloma infiltration. Thinning of the basal septum in the setting of extracardiac sarcoidosis carries a high specificity for cardiac involvement. Abnormal myocardial echotexture and eccentric hypertrophy may be suggestive of active myocardial inflammation. The presence of right-ventricular involvement as indicated by free-wall aneurysms can mimic arrhythmogenic right-ventricular cardiomyopathy. More recently, the use of myocardial strain has increased the sensitivity of echocardiography in diagnosing cardiac involvement. Echocardiography is limited in prognostication, with impaired left-ventricular (LV) ejection fraction and LV dilatation being the only established independent predictors of mortality. More research is required to explore how advanced echocardiographic technologies can increase both the diagnostic sensitivity and prognostic ability of this modality in CS.

7 July 2025 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
AAAlessia Azzu
Alessia Azzu
AAAlexios S. Antonopoulos
Alexios S. Antonopoulos
JOJoseph Okafor
Joseph Okafor
MMMarco Morosin
Marco Morosin
EAEmmanuel Androulakis
Emmanuel Androulakis
DPDudley J. Pennell
Dudley J. Pennell
Risk assessment in cardiac sarcoidosis remains challenging. This study explored the prognostic value of myocardial late gadolinium enhancement (LGE) in sarcoidosis patients. The study cohort included 324 patients with biopsy-proven sarcoidosis. LGE extent, pattern, and location were analyzed. The primary endpoint was ventricular tachycardia (VT) or ventricular fibrillation (VF) or appropriate device therapy. Secondary endpoints were hospitalization for heart failure (HF) or heart transplantation (HTx) and all-cause mortality. Over a 4.6-year follow-up, 30 patients (9.3%) reached the primary endpoint. HF/HTx occurred in 15 patients (4.6%) and all-cause mortality in 41 (12.7%). LGE extent was independently predictive of the primary endpoint (per SD change: HR: 1.03 [95% CI: 1.00-1.06]; P = 0.047), but not of HF/HTx (P = 0.30) or all-cause mortality (P = 0.50). Further to LGE extent, LGE on the right ventricular (RV) septum (HR: 5.43 [95% CI: 2.61-11.30]; P < 0.001), RV free wall (HR: 4.30 [95% CI: 1.99-9.27]; P < 0.001), and multifocal LGE (HR: 4.62 [95% CI: 2.19-9.72]; P < 0.001) were strongly predictive of the arrhythmia endpoint. Based on these findings, we propose an algorithm that identifies 4 patient subgroups and stratifies well the arrhythmia risk in biopsy-proven sarcoidosis patients (cumulative event rates: 1%, 11%, 23%, and 44%, respectively; chi-square = 44.7; P = 1.084 × 10-9). Compared with the Heart Rhythm Society classification system, this approach significantly enhanced model performance (chi-square = 8.02; P = 0.046) and risk discrimination (ΔAUC = 0.082; P = 0.019), and reclassified 43% of the population (9% to higher and 34% to lower risk categories). The authors propose a new risk stratification approach based on LGE features for assessing the risk of life-threatening ventricular arrhythmias in patients with biopsy-proven sarcoidosis.

27 October 2024 in Open Heart
Verified
Journal Article
Open access
PDF file
JOJoseph Okafor
Joseph Okafor
AAAlessia Azzu
Alessia Azzu
RARaheel Ahmed
Raheel Ahmed
SOShreya Ohri
Shreya Ohri
KWKshama Wechalekar
Kshama Wechalekar
RKRaj Khattar
Raj Khattar
Background: Echocardiography, cardiac magnetic resonance and cardiac 18fluorodeoxyglucose positron emission tomography (FDG-PET) imaging play key roles in the diagnosis and management of cardiac sarcoidosis (CS), but the relative value of each modality in predicting outcomes has yet to be determined. This study sought to determine the prognostic importance of multimodality imaging data over and above demographic characteristics and left ventricular ejection fraction (LVEF). Methods: Consecutive patients newly diagnosed with CS were included. Parameters evaluated included echocardiographic regional wall motion abnormality (RWMA), myocardial strain, LVEF, right ventricular ejection fraction (RVEF), late gadolinium enhancement (LGE) extent, SUVmax and RV FDG uptake. The primary endpoint was a composite of all-cause mortality and serious ventricular arrhythmia. Results: The study population consisted of 208 patients with mean age of 55±13 years and LVEF of 55±12%. During a median follow-up period of 46 (IQR: 18–55) months, 14 patients died and 28 suffered serious ventricular arrhythmias. On multivariable analysis, RWMA (HR for RWMA presence 2.55, 95% CI 1.27 to 5.28, p=0.008), LGE extent (HR per 1% increase 1.02, 95% CI 1.00 to 1.04, p=0.018), RVEF (HR per 1% decrease 0.97, 95% CI 0.94 to 0.99, p=0.008) and RV FDG uptake (HR for RV FDG presence 2.48, 95% CI 1.15 to 5.33, p=0.020) were independent predictors of the primary endpoint, while LVEF was not predictive. The risk of adverse events was significantly greater in those with LGE extent ≥15% (HR for ≥15% presence 3.96, 95% CI 2.17 to 7.23, p<0.001). Conclusion: In our CS population, RWMA, LGE extent, RVEF and RV FDG uptake were strong independent predictors of an adverse outcome. These findings offer an important insight into the key multimodality imaging parameters that may be used in a future risk stratification model of patients with CS.

24 April 2026 in Circulation Research
Verified
Journal Article
Open access
RTRoman Tikhomirov
Roman Tikhomirov
VBVeronika Boichenko
Veronika Boichenko
BRBenedict Reilly-O'Donnell
Benedict Reilly-O'Donnell
CLCarla Lucarelli
Carla Lucarelli
PSPrashant Kumar Srivastava
Prashant Kumar Srivastava
JGJulia Gorelik
Julia Gorelik
BACKGROUND: Cardiac fibrosis can be triggered by several pathologies, including ischemic heart disease and aortic stenosis. Cardiac fibrosis is brought about by uncontrolled ECM (extracellular matrix) deposition by myofibroblasts. IL (interleukin)-11 ( Il11 ) has been demonstrated as a trigger of multiorgan fibrosis. However, the molecular mechanisms underpinning IL-11–induced fibrosis require further characterization. Recent studies indicate that microRNA dysregulation contributes to the pathogenesis of cardiac fibrosis and can be targeted therapeutically. This study explored the hypothesis that microRNAs act as downstream effectors of IL-11–induced cardiac fibrosis. Moreover, we investigated the translational potential of IL-11–regulated microRNAs as circulating biomarkers of cardiac fibrosis in patients with aortic stenosis. METHODS: A bioinformatic microRNA target prediction analysis was used to identify candidate microRNAs regulated by IL-11. Experimental validation was performed in cardiac fibroblasts from postinfarction failing and healthy rat hearts, after IL-11 stimulation. Functional studies assessed the effects of microRNA modulation on fibrotic gene expression in cardiac fibroblasts using microRNA inhibitor–based and mimic-based transfection. Bioinformatic analysis and luciferase assay identified candidate microRNA targets downstream of IL-11. Findings were further evaluated in transverse aortic constriction and cardiomyocyte-specific Il11 -overexpression (Tg-Il11 [transgenic mouse model with cardiomyocyte-specific Il11 overexpression]) mouse models and in left ventricular tissue, peripheral plasma, and plasma extracellular vesicles from patients with aortic stenosis. RESULTS: MicroRNA-27b-5p and microRNA-497-5p were identified as novel downstream effectors of IL-11 signaling. IL-11 increased the expression of both microRNAs in cardiac fibroblasts; transfection with either microRNA inhibitor reduced, whereas microRNA mimics increased, profibrotic mRNA levels. Furthermore, microRNA-27b-5p and microRNA-497-5p converged on HIF (hypoxia-inducible factor)-1 signaling by targeting its regulator EGLN (Egl-9 family hypoxia-inducible factor). Increased microRNA levels were observed alongside reduced expression of Egln1 and Egln2 in 2 mouse models. In patients with aortic stenosis, myocardial and circulating levels of these microRNAs correlated with the severity of left ventricular fibrosis, indicating these microRNAs’ potential as new circulating biomarkers of cardiac fibrosis. CONCLUSIONS: In this study, we have newly identified the potential value of microRNA-27b-5p and microRNA-497-5p as actionable biomarkers of the profibrotic response to IL-11 in the heart. Future studies should validate the translational potential of the microRNAs as new clinical biomarkers and therapeutic targets.